Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifampin

FDA-approved product (capsule, oral), marketed as Rifadin, Rifampin, Rimactane.

Registered studies
50+
Lab records
242
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifampin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB02; FDA class Rifamycin Antibacterial

Repurposing investigation

Rifampin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli88.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae74.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis96.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 3 of 3 lab records
  • E. coli: measured active in 4 of 4 lab records
  • K. pneumoniae: measured active in 16 of 19 lab records
  • M. tuberculosis: measured active in 207 of 216 lab records
Open Rifampin in ChEMBL Registered studies below
Show the latest 150 of 242 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifampin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy

    NCT00720980 · start 2008-05

    Registered record
    Registry ID
    NCT00720980
    Conditions
    Granuloma Annulare
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-05
    Completion
    2008-07
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGranuloma Annulare
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

    NCT00621309 · start 2008-03

    Registered record
    Registry ID
    NCT00621309
    Conditions
    Adverse Drug Interactions
    Interventions
    Rifampicin; sulforaphane plus rifampicin; sulforaphane alone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-03
    Completion
    2010-09
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Drug Interactions
    InterventionRifampicin; sulforaphane plus rifampicin; sulforaphane alone
    PhasePhase 1
    Registry statusCompleted

  • Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients

    NCT00620438 · start 2008-02

    Registered record
    Registry ID
    NCT00620438
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Lumefantrine-artemether and nevirapine; lumefantrine-artemether and efavirenz; Lumefantrine-artemether and rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-02
    Completion
    2011-07
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionLumefantrine-artemether and nevirapine; lumefantrine-artemether and efavirenz; Lumefantrine-artemether and rifampicin
    PhasePhase 4
    Registry statusUnknown

  • Tuberculosis Treatment Shortening Trial

    NCT00130247 · start 2002-04-08

    Registered record
    Registry ID
    NCT00130247
    Conditions
    Tuberculosis
    Interventions
    Ethambutol; Isoniazid; Pyrazinamide; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-04-08
    Completion
    2008-11-28
    Enrolment
    394

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionEthambutol; Isoniazid; Pyrazinamide; Rifampin
    PhasePhase 3
    Registry statusCompleted

  • The Treatment of Tuberculosis in HIV-Infected Patients

    NCT00001033

    Registered record
    Registry ID
    NCT00001033
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Ethambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride; Levofloxacin; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1997-07
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionEthambutol hydrochloride; Isoniazid; Pyrazinamide; Pyridoxine hydrochloride +2 more
    PhasePhase 3
    Registry statusCompleted